The company said operating revenue for Q2 2024 was $43.2 billion, down $0.2 billion from the prior-year quarter, with operating gain of $2.8 billion and operating margin of 6.4%. The company cited attrition in Medicaid membership as the factor behind the revenue decline.

1. 01

   The company said operating revenue for Q2 2024 was $43.2 billion, down $0.2 billion from the prior-year quarter, with operating gain of $2.8 billion and operating margin of 6.4%. The company cited attrition in Medicaid membership as the factor behind the revenue decline.

2. 02

   Elevance Health said shareholders' earnings per diluted share for Q2 2024 was $9.85, up 26.4% from $7.79 in the prior-year quarter, and adjusted diluted EPS was $10.12, up 11.9% from $9.04.

3. 03

   The company said year-to-date operating cash flow through 2024 was $2.4 billion, down $6.0 billion from a year earlier. It repurchased 0.9 million shares for $462 million in Q2, and as of June 30, 2024, about $3.2 billion of Board-approved share repurchase authorization remained.

4. 04

   Elevance Health said it expects GAAP net income per diluted share for 2024 to be at least $34.05, and adjusted diluted net income per share to be at least $37.20. The company also said it declared a dividend of $1.63 per share for Q3 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.